Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

Shares of AstraZeneca PLC AZN slid 1.32% to £107.94 Monday, on what proved to be an all-around great trading session for the ...

SYDNEY, Jan. 21, 2025 /PRNewswire/ -- Trinasolar, a global leader in smart PV and energy storage, has partnered with Smart ...

Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...

New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

IonQ's strong revenue growth and partnerships with industry leaders are promising, but high operating expenses and reliance ...

Dr. Patrick Hemmons travelled to Seattle to get an RSV shot for his daughter. He says he hopes to see nirsevimab become more ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...